DiaMedica Therapeutics (DMAC) financial statements
Net income was -$33M.
Free cash flow was -$29M.
The diluted share count rose 691% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from DiaMedica Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $500,000 | — | — | — | — | — | — | — |
| Research and development | $3M | $5M | $8M | $8M | $9M | $8M | $13M | $19M | $25M |
| Selling, general and admin | $1M | $3M | $4M | $4M | $5M | $6M | $8M | $8M | $10M |
| Operating income | -$5M | -$7M | -$12M | -$13M | -$14M | -$14M | -$21M | -$27M | -$34M |
| Pre-tax income | -$4M | -$6M | -$11M | -$12M | -$14M | -$14M | -$19M | -$24M | -$33M |
| Income tax | — | $80,000 | $31,000 | $27,000 | $28,000 | $28,000 | $43,000 | $30,000 | $28,000 |
| Net income | -$4M | -$6M | -$11M | -$12M | -$14M | -$14M | -$19M | -$24M | -$33M |
| EPS (diluted) | -$0.72 | -$0.74 | -$0.89 | -$0.78 | -$0.65 | -$0.52 | -$0.60 | -$0.60 | -$0.70 |
| Diluted shares | 6M | 8M | 12M | 16M | 21M | 26M | 33M | 40M | 47M |
| Operating margin | — | -1352.2% | — | — | — | — | — | — | — |
| Net margin | — | -1146.8% | — | — | — | — | — | — | — |
Balance sheet
Fiscal years, from DiaMedica Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $1M | $17M | $8M | $28M | $45M | $34M | $53M | $44M | $60M |
| Receivables | $80,000 | $780,000 | $823,000 | $340,000 | $130,000 | $82,000 | $369,000 | $236,000 | $258,000 |
| Total current assets | $1M | $18M | $9M | $28M | $45M | $34M | $54M | $45M | $61M |
| Property, plant and equipment | $37,000 | $96,000 | $64,000 | $74,000 | $70,000 | $136,000 | $131,000 | $148,000 | $145,000 |
| Total assets | $2M | $18M | $9M | $28M | $46M | $34M | $54M | $46M | $61M |
| Total current liabilities | $1M | $1M | $1M | $2M | $2M | $2M | $3M | $5M | $5M |
| Total liabilities | $1M | $1M | $1M | $2M | $2M | $3M | $3M | $6M | $5M |
| Shareholders' equity | $799,000 | $17M | $8M | $26M | $44M | $32M | $51M | $41M | $56M |
| Net debt | -$1M | -$17M | -$4M | -$7M | -$5M | -$5M | -$5M | -$3M | -$16M |
Cash flow
Fiscal years, from DiaMedica Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4M | -$6M | -$9M | -$9M | -$12M | -$12M | -$19M | -$22M | -$29M |
| Capital spending | $22,000 | $50,000 | $2,000 | $47,000 | $22,000 | $81,000 | $24,000 | $25,000 | $40,000 |
| Free cash flow | -$4M | -$6M | -$9M | -$9M | -$12M | -$12M | -$19M | -$22M | -$29M |
| Stock-based compensation | $409,000 | $620,000 | $1M | $2M | $2M | $2M | $2M | $2M | $4M |
| Free cash flow margin | — | -1149.2% | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DMAC.
Open DMAC in InvestinglyQuestions
How much free cash flow does DiaMedica Therapeutics generate?
-$29M in fiscal 2025 (operating cash flow minus capital spending).
From DiaMedica Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.